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ABSTRACT 
Neonatal abstinence syndrome (NAS) in infants presents unique challenges in feeding 
and weight gain. The unpredictable clinical manifestations associated with the newborns 
withdrawal from exposure to drugs in utero can lead to costly delays in transition of the infant 
out of the Neonatal Intensive Care Unit (NICU).The purpose of this review of literature was to 
explore feeding positions and nutritional intake with the greatest impact on weight gain in infants 
with neonatal abstinence syndrome (NAS) following delivery. The secondary purpose was to 
compare the clinical manifestations of infants with NAS that influence nutritional intake and 
their relationship to length of time and cost of stay in the NICU. A review of literature was 
performed using multiple databases. Articles focusing on feeding position and nutrition intake 
were identified for interventions to effectively promote weight gain, while reducing clinical 
manifestations common in infants with NAS. Articles exploring improved feeding and weight 
gain in infants with NAS and reduced length of stay in the NICU were also synthesized for cost 
reductions to the facility. Results from 12 studies comparing various feeding positions that 
optimized nutrition, and reduced negative clinical manifestations in infants with NAS were 
synthesized for content relevant to the research questions. Results suggest a relationship between 
placing infants in the c-position, and side-lying position to reduce sensory stimulation, with 
reducing clinical manifestations for infants actively experiencing withdrawal symptoms from 
NAS. Providing chin and cheek support as needed, decreasing eye contact during feeding 
periods, and providing darker quiet environments all play an important role in allowing infants 
with NAS to optimize their weight gain. As previously stated, to manage nutritional intake and 
optimize weight gain, reduction of clinical manifestations through pharmacological and non-
pharmacological interventions must be actively incorporated into the infants’ plan of care. 
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INTRODUCTION 
Neonatal abstinence syndrome (NAS), in conjunction with the opioid epidemic, has seen 
a successive incremental rise in the United States (US) in the past 20 years, with an increase of 
300% from 1.5 hospital births in 1999 to 6 per 1,000 hospital births as of 2013 (Ko et al., 2016). 
This is the equivalent of one opioid dependent infant born every 25 minutes (“Dramatic 
Increases in Maternal”, 2019). The treatment of NAS in infants born addicted often involve 
pharmacologic and non-pharmacological therapies to manage the individualized clinical 
manifestations. Clinical manifestations include central nervous system deficits such as 
irritability, autonomic dysfunction, and gastrointestinal signs such as excessive sucking, reduced 
quality and quantity of feeding resulting in poor weight gain, vomiting, and loose stools (Logan, 
Brown, Hayes, 2013).  Interventions aimed at reducing the negative effects of addiction involve 
consistent care regimens that promote weight gain and growth, while minimizing CNS 
disturbances. In most instances, a multidisciplinary approach is instituted using drug therapy and 
scheduled care routines, however implementation of care related to feedings can be inconsistent 
and vary between health care providers.  
The use of pharmacological agents to reduce the severity of CNS clinical manifestations 
in infants with NAS is well established. However, interventions aimed at feeding methods to 
improve digestion and increase nutrition levels have not been adequately studied in the context 
of overall weight gain. According to a study conducted by Wachman, Byun, & Philipp (2010), 
breastfeeding rates among opioid-dependent women were low, with 75% of eligible women 
electing not to breastfeed.  Colostrum and breast milk via breastfeeding in comparison to high 
calorie formula via bottle feeding warrants further exploration in relation to weight gain and 
nutrition intake for infants with NAS. Equally important is the reduction of clinical 
 2 
manifestations interfering with nutritional intake and proper positioning of infants with NAS 
during feeding, with regards to breast-feeding or formula feeding methods.  
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PROBLEM 
There are many physiologic and psychosocial causes of failure to thrive that can 
potentially affect an infant’s weight. Failure to thrive is defined as “a state of undernutrition due 
to inadequate caloric intake, inadequate caloric absorption, or excessive caloric expenditure. In 
the United States, unintentional weight loss and poor nutritional intake is prevalent in 5 to 10 
percent of children in primary care settings” (Cole & Lanham, 2011). 
Physiologic causes of failure to thrive can include, damage to the brain or central nervous 
system, anemia, metabolic disturbances, chronic infections, cardiovascular or pulmonary 
disturbances, organ dysfunction, hormone dysfunction, or low birth weight (Failure to thrive, 
2019). Psychosocial causes can include, psychological, social, or economic problems within the 
family dynamic. Additionally, “emotional or maternal deprivation, substance abuse, or lack of 
knowledge about proper feeding techniques are also related to nutritional deprivation” (Pediatric 
Poor Growth, 2019). Often times, the specific cause of failure to thrive cannot be determined.  
However, infants affected by NAS have unique concerns regarding weight gain. 
Common clinical manifestations that impact infants affected by NAS include diarrhea, vomiting, 
irritability, inadequate nutrition, leading to poor weight gain. Clinical manifestations associated 
with infants born with NAS present challenges to improving feeding patterns and styles, 
promoting weight gain, and ultimately meeting neonatal milestones, to transition out of the 
Neonatal Intensive Care Unit (NICU).  
The research question in this literature review focused on the socio-economic factors to 
identify, promote, and implement efficient feeding positions and styles, as well as quality of 
nutritional intake for infants with NAS in order to decrease overall time spent in the NICU, and 
cost.  
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PURPOSE 
The purpose of this literature review was to examine current research regarding factors 
that had the greatest impact on weight gain in infants with NAS following delivery, with respect 
to various feeding positions and styles, and the quality of nutritional intake.  
The outcome of this review was to understand how interventions can be implemented to 
decrease the amount of central nervous system disturbances to prevent, maintain, and improve 
overall weight gain, and the health of infants affected by NAS. Additionally, this review 
explored various socio-economic factors, to identify, promote, and implement interventions that 
potentially lead to an overall decrease in time and cost spent in the NICU. Sufficient evidence 
exists to suggest that increased weight gain is correspondent with shorter duration in the NICU. 
However, more support is needed to determine how these various feeding positions, and quality 
of nutritional intake, whether it be breast milk or formula, promote greater overall health, 
increased weight gain, and decreased overall time spent in the NICU.  
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METHOD 
A literature review was performed using research articles from 1999 to present, regarding 
factors that have the greatest impact on weight gain in infants with NAS associated with feeding 
positioning, and styles, quality of nutritional intake, and reduction of clinical manifestations. The 
focus was also to relate to various socio-economic factors to identify, promote, and implement 
interventions that will potentially lead to an overall decrease in time and cost spent in the NICU. 
Databases used to search for articles included Cumulative Index to Nursing & Allied Health 
Literature (CINAHL), Elton B. Stephens Co. (EBSCOhost), Education Resources Information 
Center (ERIC), Medical Literature Analysis and Retrieval System Online (Medline), and 
PsycINFO databases. Searches used a combination of the following terms: Neonatal abstinence 
syndrome*, clinical manifestations*, symptoms*, benefit*, NICU*, weight gain*, feeding*, 
nutrition*, high-calorie formula*, breast feeding*, CNS disturbances*, vomiting*, irritability*, 
diarrhea*, cost*, and duration*. Inclusion criteria consisted of 1) published research in English, 
2) positions and styles of feeding approach, quality of nutrition, and 3) identified interventions 
effectively promoting weight gain, while reducing clinical manifestations common in infants 
with NAS.  
The data was conformed into tables that synthesized the relationship between the various 
feeding positions, and styles, as well as the quality of nutrition related to the reduction of clinical 
manifestations in infants with NAS. Any additional information on NAS based on reduction of 
clinical manifestations, reduced duration of stay in the NICU, and cost-effectiveness, was tabled 
based on the obtained data. The data was used to reveal evidence that could be used to develop 
guidelines for promoting overall weight gain, and the reduction of clinical manifestations in 
infants with NAS.  
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BACKGROUND 
Neonatal abstinence syndrome (NAS), is the result of behavioral and physiological 
clinical manifestations that an infant may experience while withdrawing from narcotics (opioids) 
and other pharmacologic agents from exposure in utero (Rojan, 2017). Though there are 
recurring clinical manifestations that occur throughout most cases of NAS, the presentation of 
NAS is unpredictable, and infants will display individualized manifestations dependent upon the 
severity of withdrawal, type of drug, and age of the infant (MacMullen, Dulski & Blobaum, 
2014).  
There are two major types of NAS (MacMullen, Dulski & Blobaum, 2014). Prenatal 
NAS is widely recognized, and is due to the prenatal maternal use of substances. Withdrawal 
symptoms will occur once the placenta no longer has access to the substance provided during 
pregnancy. Common pharmacological agents used during pregnancy that are implicated in 
prenatal NAS consist of: opiates, barbiturates, stimulants such as cocaine, sedatives, ethanol, 
marijuana, and nicotine (MacMullen, Dulski & Blobaum, 2014). Postnatal NAS occurs when 
there is an abrupt discontinuation of analgesia, such as fentanyl or morphine. It usually occurs 
after prolonged drug exposure for post-procedure pain management and/or sedation. However, 
chronic opioid exposure is the most common source of NAS (MacMullen, Dulski & Blobaum, 
2014). 
Maternal substance abuse is a preventable cause of mental, physical, and psychological 
problems in infants and children, which can lead to classification of prenatal NAS. Drug abuse in 
pregnancy, and neonatal psychomotor behavior consistent with withdrawal from opiate and 
polydrug withdrawal is currently a significant clinical and social problem. An estimated average 
of 5.4% of pregnant women between 15 to 44 years of age used illicit drugs in 2012-2013. The 
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highest rate occurred in those 15to 17 years of age, (14.6%), followed by women 18 to 25 years 
of age (8.6%), and those between  26 to 44 years (3.2%) (“Substance Use and Mental Health 
Estimates”, 2014).  
Postnatal NAS occurs when an abrupt discontinuation of opioid analgesia occurs, usually 
after prolonged drug exposure. In the Neonatal Intensive Care Unit (NICU), fentanyl is the most 
commonly administered analgesic. This is a potent, rapid acting, synthetic opioid with a relative 
lack of hemodynamic side effects. Fentanyl and morphine have shown to produce a high rate of 
opioid withdrawal when administered to critically ill infants. Tolerance and withdrawal 
symptoms may occur after 5 or more days of continuous infusion of fentanyl, and may occur 
more often with fentanyl than morphine (Hamdan, 2017).  
Common opiates and narcotics associated with NAS include: Codeine, fentanyl, heroin, 
methadone, meperidine, oxycodone, morphine, hydromorphone, butorphanol, pentazocine, 
propoxyphene, chlordiazepoxide, buprenorphine, barbiturates, caffeine, cocaine, selective 
serotonin reuptake inhibitors, antihistamines, ethanol, marijuana, nicotine, phencyclidine, 
meprobamate, glutethimide, ethchlorvynol, diazepam and lorazepam (Hamdan, 2017).  
Drugs are transferred from the mother to the fetus via the placenta through active 
transport which requires energy to move fluids into the cell. Passive diffusion requires no energy 
for movement. Pinocytosis, moves fluid by invagination of the cell membrane. The ease of 
transport depends on the size of the drug molecule, its lipophilicity, the pKa (acid ionization 
constant) of the compound, and the pH of the blood. During delivery of the fetus, the passage of 
the drug is interrupted, resulting in the development of a withdrawal symptom in the neonate. It 
is theorized that withdrawal can cause molecular alterations that may produce systemic, 
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behavioral, and cognitive symptoms. However, the mechanisms of withdrawal in a neonate are 
poorly understood (MacMullen, Dulski & Blobaum, 2014).   
Women undergo many physiologic changes throughout their pregnancy. Examples of 
common physiologic changes that new mothers may face include nausea, vomiting, sensitivity to 
odors, gastric reflux, and constipation. This pregnancy-related constipation is the result of 
decreasing peristalsis in the gastrointestinal tract. Peristalsis is the involuntary wave-like 
movement that moves food throughout the gastrointestinal tract (Peristalsis, 2019). “Smooth 
muscle relaxation and decreased peristalsis occur related to the influence of progesterone. 
Elevated progesterone levels cause smooth muscle relaxation, which results in delayed gastric 
emptying and decreased peristalsis” (Kyle & Ricci, 2009).   
Many women use some type of drug, substance, or medication during pregnancy, and 
often times don’t recognize or understand the effects that these substances may have on their 
developing fetus. With decreasing peristalsis throughout the gastrointestinal tract, the rate of 
absorption for these substances is prolonged, and therefore poses a greater risk for negative 
teratogenic effects. Though clinical manifestations are individualized for each infant affected by 
NAS, there are general effects that will present themselves due to generalized use of drugs, 
substances, or medications during pregnancy. These general effects include, but are not limited 
to: interfering with normal fetal development, damaging the infant’s organs, damaging the 
placenta and putting the infant’s life at risk, increasing the risk of miscarriage, or bringing on 
premature labor (Pregnancy- medication, drugs, and alcohol, 2012). Bowel function and rooting 
in the infant are impaired as a result of use of substances during pregnancy. NAS infants lose the 
drive to root, or the will to suckle, and have impaired bowel function, resulting in lethargy, 
which can lead to poor weight gain.  
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As previously stated, NAS is individualized, and infants will present with varying 
manifestations. However, there are common manifestations that are recognized and associated 
with infants experiencing NAS. The manifestations exhibited are heavily dependent upon the 
type of drug used during pregnancy, as well as the amount of exposure the fetus had in utero. 
The effect of drugs on body systems is influenced by the type of drug, the combination of drugs, 
the amount and frequency of use, the trimester in which the drug is used, the timing of 
withdrawal, and the genetic susceptibility of the fetus/neonate (MacMullen, Dulski & Blobaum, 
2014). Infants exposed to opioids in utero are likely to present with manifestations such as: 
hyperirritability, GI dysfunctions such as excessive sucking, poor feeding, regurgitation, and 
diarrhea. They may also experience tremors, high-pitched crying, increased muscle tone, 
seizures, nasal congestion, hyperthermia, and tachypnea. Unfortunately, it is not widely known 
how healthcare professionals and those caring for infants with NAS can decrease GI 
disturbances, and increase opportunities for weight gain. Increased awareness among healthcare 
professionals is essential when caring for infants with NAS in relation to feeding quality, and 
positioning, to decrease the clinical manifestations related to poor weight gain.  
Infants exposed to cocaine in utero may not experience any significant withdrawal 
syndromes due to the short period of time in which a withdrawal related to cocaine may occur. 
Similarly, infants exposed to benzodiazepines may not experience a withdrawal syndrome. 
Though Cannabis/Marijuana is a substance that has been known to be used during pregnancy, the 
current effects of Cannabis/Marijuana on the infant, and infant feeding are not yet fully 
understood. Alcohol exposed infants may present with hyperactivity, central nervous system 
(CNS) dysfunction, fetal alcohol syndrome (FAS), jitteriness, irritability, hyperreflexia, 
hypertonia, poor suck, tremors, seizures, poor sleep patterns, hyperphagia, and diaphoresis. 
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Infants exposed to selective secretion reuptake inhibitors (SSRIs) may present with jitteriness, 
respiratory distress, and sleep disturbances (MacMullen, Dulski & Blobaum, 2014).  
 
Summary 
 Neonatal abstinence syndrome is an individualized condition that varies between infants. 
Though there are many common clinical manifestations, each infant will present with their own 
challenges based on type and duration of drug exposure in utero (MacMullen, Dulski & 
Blobaum, 2014).  Many women use some type of drug, substance, or medication during 
pregnancy, and often times don’t recognize or understand the effects that these substances may 
have on their developing fetus. It is not widely understood how healthcare professionals can 
decrease gastrointestinal disturbances and other manifestations, while increasing opportunities 
for weight gain. 
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RESULTS 
Twelve studies related to neonatal abstinence syndrome and reduction of clinical 
manifestations were included in this review of literature. All studies were published in the past 
twenty years. Seven articles provided follow-up data on previously conducted cohort studies, one 
case study was included, one mixed-methods pilot study was included, one article included a 
focus group methodology, one article was composed of a case series, and one prospective cohort 
study was also included. Mixtures of both qualitative and quantitative studies were included in 
this literature review. 
Neonatal Abstinence Syndrome and Related Outcomes 
The literature review revealed major themes pertaining to neonatal abstinence syndrome 
and the reduction of clinical manifestations to optimize weight gain in infants with this 
condition. Studies described self-reported data trends and outcomes related to breastfeeding 
promotion, rooming-in promotion, pharmacological interventions, and non-pharmacological 
interventions.  
Breastfeeding Promotion 
 Seven studies focused on the promotion of breastfeeding by mothers whose infants are 
affected with neonatal abstinence syndrome, so long as there are no outstanding 
contraindications, and appropriate therapies have been commenced (Abdel-Latif et al., 2006; 
Gottesman, Chang, Feldman, & Ziegler, 2018; Isemann, Meinzen-Derr, & Akinbi, 2011; 
MacVicar, Humphrey, & Forbes-McKay, 2017; Pritham, 2012; Pritham, Paul, & Hayes, 2012; 
Short, Gannon, & Abatemarco, 2016). In a retrospective cohort study, the effects of breast milk 
feeding were assessed in comparison with the severity of neonatal abstinence syndrome in a 
population of affected infants. Among 190 infants, the length of stay for those who were 
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breastfed was 14.7 days, compared to 19.1 days for those infants who were non-breastfed 
(Abdel-Latif et al., 2006). Infants were assessed using the Finnegan Scoring System. The mean 
scores for the first 9 days of life were considerably lower in infants with breastmilk intake. 
Additionally, the median time to withdrawal occurred considerably later in breastmilk infants 
when compared to infants in the formula group (Abdel-Latif et al., 2006). 
 One infant in a case study was monitored to track tolerance to feedings, daily weight 
gain, growth patterns, velocity goals, head circumferences, length measurements, changes in 
electrolytes, and implementation of nutrition-related medications. These goals were continually 
adjusted to lessen the severity of NAS, and the clinical manifestations associated with it, that the 
infant was experiencing. The infant started with transitional formula for intake at the beginning 
of the study, then moved to a 20-calorie per ounce term formula, where weight gain (36.2 g/d) 
increased. Then, the infant moved to 24- calorie per ounce term formula, where weight (7.4 g/d) 
continued to increase. The benefits of breastfeeding for this vulnerable group outweigh any of 
the potential risks, granted that the mother is on a stable dose of methadone or buprenorphine, 
and is actively involved in an opioid management program (Gottesman, Chang, Feldman, & 
Ziegler, 2018). 
 In a retrospective cohort study, maternal breast milk feedings were associated with 
shorter median duration of methadone therapy in both term and preterm infants. Compared to 
infants who were formula-fed (median 18.5 days), consumption of maternal breast milk was 
associated with shorter length of stay (median 12.5 days) (Isemann, Meinzen-Derr, & Akinbi, 
2011). 
 In a mixed-methods pilot study, thematic analysis generated 5 key themes relating to 
breastfeeding support and substance exposure. These themes included: breastfeeding skill and 
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knowledge, psychological factors, person-centered approach, environmental modifications, and 
postnatal experience on breastfeeding. Breastfed infants in this study had a shorter hospital stay 
than infants who were formula-fed (10.8 and 30.0 days, respectively). These infants were also 
less likely to require pharmacotherapy, and displayed a less significant course of withdrawal 
(MacVicar, Humphrey, & Forbes-McKay, 2017). 
 In an additional retrospective study, there were statistically significant differences 
between infants who were formula-fed and infants who were breastfed in relation to the 
commencement of pharmacological treatment. Three infant feeding methods included in this 
study (formula, breast, or mixed formula and breast) revealed significant differences in neonatal 
abstinence syndrome treatment between formula and breastfed infants, but not between the 
formula-fed infants and infants who received a mixture of formula and breastmilk. Opioid-
dependent women that are actively participating in buprenorphine maintenance therapy were 
encouraged to breastfeed, so long as there are no outstanding contraindications present (Pritham, 
2012).  
 Furthermore, in another retrospective study, infants with prenatal exposure to methadone 
who were breastfed were discharged home earlier than those infants who were formula-fed. It is 
suggested that breastfeeding may be protective for neonates withdrawing from opioids. Overall 
breastfeeding is associated with a decreased rate of infant treatment for withdrawal from prenatal 
methadone or buprenorphine exposure. Breastfeeding should be permitted and encouraged so 
long as the maternal urine drug screen is negative for illicit substances upon admission (Pritham, 
Paul, & Hayes, 2012). 
 Correspondingly, in another retrospective cohort study, it was found that NAS infants 
who are breastfed have a significantly shorter length of stay than non-breastfed NAS infants, 
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even after controlling for differences in maternal and infant characteristics. Lower rates of 
breastfeeding among NAS infants were not unexpected, this tendency could be due to higher 
NICU admission rates and/or the physical manifestations more commonly found in this 
population, making breastfeeding an additional challenge. However, the act of breastfeeding 
plays an additional role in impacting NAS infants, rather than the breast milk intake alone (Short, 
Gannon, & Abatemarco, 2016). 
Rooming-in Promotion 
 Three studies described the promotion of mothers and infants rooming-in, and the 
benefits that may prevail with infants with NAS.  
 A retrospective cohort study was conducted to evaluate the effects of rooming-in on the 
incidence and severity of NAS among opioid-exposed newborns and on the proportion of 
mothers who regain custody of their babies at hospital discharge. Rooming-in was associated 
with substantially reduced rates of newborn treatment with morphine, length of morphine 
treatment, vomiting, admission to a level II nursery, and length of stay in the hospital. Mothers 
who roomed-in were much more likely to retain custody of their newborns. Newborns who 
roomed-in were much more likely to be discharged in the custody of their mothers than infants in 
other groups. This study found that overall, rooming-in is associated with easing newborns’ 
transition and promotes better care from the mother (Abrahams et al., 2007). 
In a case series, a rooming-in program was implemented to support close uninterrupted 
contact between opioid-dependent women and their infants in order to decrease the severity of 
NAS scores, lessen the need for pharmacotherapy, and shorten hospital stays. The mean length 
of stay was significantly shorter among those in the rooming-in cohort (7.9 days vs 24.8 days). 
Rooming-in could potentially reduce bed use and save hospital resources, while preventing 
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patients from dealing with negative psychosocial stressors. Rooming-in was also associated with 
a decreased need for pharmacotherapy from 88.3% of infants receiving care in the NICU, to only 
14.3% of those rooming-in (Newman et al., 2015). 
In a retrospective cohort study, the association between breastfeeding and length of 
hospital stay among infants diagnosed with NAS was examined. This study found that rooming-
in and uninterrupted post-partum contact between mother and infant has shown to positively 
affect infants by NAS (Short, Gannon, & Abatemarco, 2016). 
Pharmacological Interventions 
Nine studies discussed the importance of pharmacological interventions in the treatment 
regimen for infants with NAS.  
In a retrospective cohort study previously discussed, pharmacological treatment began if 
Finnegan scores exceeded 8 on 2 occasions or was greater than 10 on 1 occasion. Morphine 
commenced for poly-drug and opiate-exposed infants and increased or decreased 10% every 2-3 
days to maintain a Finnegan score of less than 8. Phenobarbital was given in addition to 
morphine if symptoms were uncontrolled. Overall treatment in the breast milk group was 20 
days less than those in the formula group, while the maximum amount of morphine was lower in 
the breast milk group (Abdel-Latif et al., 2006).  
 In the reviewed case study, the infant was given morphine and phenobarbital, and these 
medications were titrated accordingly based on Finnegan scores (Gottesman, Chang, Feldman, & 
Ziegler, 2018). In the second month of treatment, the infant switched to a 20-calorie per ounce 
term formula, and slowly began to wean from phenobarbital and morphine. However, the infant 
re-exhibited signs of withdrawal through hyperirritability, and high-pitched cries, therefore 
morphine and phenobarbital were continually titrated. The infant continued to show signs of 
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withdrawal at month 3. At month 4, phenobarbital was titrated, methadone was added to support 
withdrawal, and morphine was removed. At month 5, Finnegan scores were decreasing, while 
weight gain was increasing. At month 6, after transitioning to 24-calorie per ounce term formula 
with iron, the infant had a weight gain of 7.4 g/d, Finnegan scores were low, and methadone was 
discontinued (Gottesman, Chang, Feldman, & Ziegler, 2018). Pharmacological therapy is a 
necessity for the treatment regimen in helping infants with NAS.  
 A retrospective cohort study discussed the factors that impact maternal and neonatal 
factors that impact response to methadone therapy for neonatal abstinence syndrome (Isemann, 
Meinzen-Derr, & Akinbi, 2011). Infants were scored using the Finnegan Scoring System, and 
received methadone per protocol if signs of NAS continued, post-non-pharmacological 
management. Infants that required adjunctive therapy with phenobarbital were born of mothers 
on higher doses of methadone and had longer lengths of stay compared with infants managed 
with methadone therapy alone. Maternal methadone maintenance dose during pregnancy 
positively correlated with overall length of stay. There was an inverse relationship between the 
amount of mother’s breast milk ingested, and overall length of stay (Isemann, Meinzen-Derr, & 
Akinbi, 2011).  
 A mixed-methods pilot study consisted of an intervention and a control group. The 
intervention group received support based on practical breastfeeding advice, promotion of 
maternal self-efficacy through encouragement and persuasion, and provision of neonatal self-
consolation techniques within a low-stimuli environment. Of the intervention group, 28% 
required pharmacotherapy for severe withdrawal compared with 57% in the control group 
(MacVicar, Humphrey, & Forbes-McKay, 2017). 
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 In a focus group methodology, information was gathered from 12 participants including 
NICU nurses and speech therapists through two separate focus group discussions (Maguire, 
Shaffer-Hudkins, Armstrong, & Clark, 2018). The study revealed that pharmacological 
management with opioid replacement therapy is of value, because it dampens the central nervous 
system irritability that leads to disrupted feeding, and therefore to increased mal-adaptive 
manifestations and poor weight gain (Maguire, Shaffer-Hudkins, Armstrong, & Clark, 2018).  
 A retrospective cohort study conducted by Pritham (2012) found that exposed neonates 
receiving NAS treatment either through receiving methadone maintenance therapy or 
buprenorphine maintenance therapy who were also breastfed began first line therapy with 
phenobarbital 1.1 days later and their length of stay was shorter by 9.4 days as compared to 
formula-fed neonates or neonates who received formula and breastmilk (Pritham, 2012). 
 An additional retrospective cohort study consisted of two groups, including: opioid-
dependent pregnant women on methadone maintenance therapy (MMT), and opioid-dependent 
pregnant women on buprenorphine maintenance therapy (BMT). This study found that 
benzodiazepine use is a predictor variable for length of treatment for NAS. Neonates exposed to 
methadone and benzodiazepines while in utero and who were born at term had significantly 
longer length of treatment for NAS when compared with unexposed neonates or to exposed 
neonates born prematurely. Also, associated exposure to SSRIs with MMT did not prolong 
length of stay. Additionally, neonates exposed to buprenorphine experienced less severe NAS 
and shorter length of stay than those exposed to methadone by seven days (Pritham, Paul, & 
Hayes, 2012). 
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Non-Pharmacological Interventions 
Five studies discussed the importance of non-pharmacological interventions in infants 
with neonatal abstinence syndrome.  
A mixed-methods pilot study evaluated the feasibility of an intervention that included 
environmental modifications such as minimizing external stimuli through temperature control, 
reduced activity, and regulated noise (MacVicar, Humphrey, & Forbes-McKay, 2017). Infants in 
this study were nursed in a shielded cot and canopy to limit exposure to light. The mother was 
provided and instructed with consolation techniques including non-nutritive sucking, and loose 
swaddling for self-soothing purposes for the infant. The intervention group had higher 
breastfeeding rates, and higher confidence in terms of breastfeeding ability than those in the 
control group (MacVicar, Humphrey, & Forbes-McKay, 2017). 
A focus group methodology by Maguire, Shaffer-Hudkins, Armstrong, and Clark (2018) 
showed that neurobehavioral organization plays an important role in successful feeding. Often 
times, the baby is not ready to feed when picked up, as a result nursing assessment of feeding 
cues were crucial for success when feeding infants with NAS. Additionally, a technique that 
achieved feeding goals on a certain day may not work again the next day, requiring continued 
trial and error by providers. Swaddling and decreasing environmental stimuli can assist in 
calming and comforting the infant during feeding, thereby increasing weight gain in a timely 
manner.  
Swaddling is one of the few non-pharmacological interventions reported to be effective in 
infants with NAS to reduce crying. Swaddling can also decrease startles and sleep arousals, 
which leads to increased sleep time and continuity of restful states between feedings. The C-
position holding method was discussed, where the infant is placed on his side, lying on the 
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informants’ legs, with arms slightly flexed, keeping the head of the infant slightly elevated by 
crossing one leg over the other. Warm baths have been used to calm infants with NAS prior to 
feeding as well. Informants in this study emphasized the importance of vertical versus horizontal 
rocking to calm the infant. Most informants reported trying all available nipples until they found 
the nipple most effective for the infant, and most reported using chin and cheek support as 
needed (Maguire, Shaffer-Hudkins, Armstrong, & Clark, 2018) in infants with NAS to increase 
amount of time during feeding sessions. 
A study randomized to intervention showed that even highly irritable infants can enjoy a 
significant reduction in distress by being laid in the prone position. Infants experiencing 
withdrawal showed significantly lower levels of distress and lower withdrawal scores when laid 
in the prone position compared with similar infants kept supine (Maichuk, Zahorodny, & 
Marshall, 1999).  
A retrospective cohort study by Short, Gannon, and Abatemarco (2016) showed that 
other nonpharmacological interventions both compliment and support the act of breastfeeding, 
such as skin to skin contact, and kangaroo care. These positions can lead to optimized weight 
gain, and reduction in length of stay, and overall cost spent in infants with NAS having difficulty 
feeding (Short, Gannon, & Abatemarco, 2016). 
A prospective design, with a random assignment of drug-exposed and non-exposed 
newborns to either a control or experimental group, showed that through auditory, tactile, visual, 
and vestibular (ATVV) intervention, the drug-exposed experimental group trended toward 
greater active sleep. The non-exposed infants who received ATVV intervention had 19% more 
alertness during the intervention period than the non-exposed control infants during the same 
period of observation. ATVV intervention consisted of a 15-minute procedure, consisting of 
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infant-directed talk, continuous throughout the procedure (auditory), 10 minutes of light 
stroking/infant massage (tactile), eye-to-eye contact during alert periods (visual), and vertical 
rocking of the swaddled infant for 5 minutes post massage (vestibular) (White-Traut et al., 
2002). This intervention is to be conducted prior to feeding intervention to help dampen the 
central nervous system, and optimize greater weight gain during feeding periods.  
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DISCUSSION 
 The studies reviewed in this work provide insight into the common clinical 
manifestations of infants with neonatal abstinence syndrome. Research findings revealed the 
main outcomes of interventions commonly used in treating infants with NAS, to increase the 
opportunity for weight gain. Though the reviewed literature did not have a confirmatory, singular 
agreement on the interventions for feeding positions with regard to NAS infant weight gain, 
there are main themes that prevailed through multiple articles that were shown to positively 
affect outcomes of infants with NAS, while optimizing periods for weight gain. 
 
Breastfeeding Promotion 
In the absence of outstanding contraindications, including mothers currently using 
methadone maintenance therapy (MMT), buprenorphine maintenance therapy (BMT), or other 
appropriate and equal therapies, breastfeeding should be promoted by nurses and healthcare 
professionals in efforts to help reduce the severity of neonatal abstinence syndrome, and 
optimize weight gain in infants. Several studies had positive correlations with breastfeeding in 
comparison to reduction in length of stay, and reduction in likelihood of requiring 
pharmacological treatment than infants who were formula-fed (Abdel-Latif et al., 2006; 
Gottesman, Chang, Feldman, & Ziegler, 2018; Isemann, Meinzen-Derr, & Akinbi, 2011; 
MacVicar, Humphrey, & Forbes-McKay, 2017; Pritham, 2012; Pritham, Paul, & Hayes, 2012; 
Short, Gannon, & Abatemarco, 2016).  
Infants in multiple articles were assessed using the Finnegan Scoring System (Abdel-
Latif et al., 2006; Gottesman, Chang, Feldman, & Ziegler, 2018; Isemann, Meinzen-Derr, & 
Akinbi, 2011; MacVicar, Humphrey, & Forbes-McKay, 2017; Newman et al., 2015). This 
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scoring system is broken into three different systems including, central nervous system 
disturbances, metabolic vasomotor/respiratory disturbances, and gastrointestinal disturbances. 
Infants are scored with varying numbers of 1-3, dependent on the specific clinical manifestations 
in each system. Infants are assessed every 2 hours with the Finnegan Scoring System, while daily 
weights are additionally recorded. (“The Assessment and Management”, 1992). During this time, 
healthcare providers can continually monitor an infants tolerance to feedings, daily weight gain, 
growth patterns, velocity goals, head circumferences, length measurements, changes in 
electrolytes, and implementation of pharmacological interventions. Health care providers can 
track changes, monitor interventions, and keep detailed records, about feeding and weight gain to 
advocate and support infants with NAS and their families.  
Management of the clinical manifestations associated with infants exposed to drugs in 
utero is useful in promoting feeding and positioning during feeding to ensure weight gain. 
Promotion of breastfeeding and skin-to-skin feeding options are of value to feeding infants with 
NAS when safe. Though breastfeeding may not be desired, or possible in every case, education 
on the benefits and drawbacks directed at the infant’s mother and how and the positive affect on 
their infants weight gain and immunologic protection is of value. The literature shows significant 
correlation between breastfeeding in infants with NAS and decreasing length of stay in the 
hospital, thereby reducing overall cost of stay. Breastfeeding also has been correlated with 
decreased need for pharmacological intervention in infants with NAS, and a less severe course of 
withdrawal.  
Lower rates of breastfeeding among NAS infants is not unexpected and associated with 
higher NICU admission rates and/or the physical manifestations commonly found in women 
using drug therapy during pregnancy. Healthcare providers can assist in creating an environment 
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that is more feasible to breastfeeding, and promote the significance of breastfeeding for 
vulnerable populations, such as infants born to women using drugs during pregnancy. Discussion 
about the immunologic and protective benefits of breastfeeding can improve both the women’s 
health and their infants. Education provided to families about interventions to help control the 
physical manifestations of NAS that can be barriers to the breastfeeding process should be 
explored. Understanding the mechanics of breastfeeding can be difficult for women after birth of 
their child however, healthcare can be prepared and willing to teach proper techniques conducive 
to breastfeeding an infant with NAS.  
 
Rooming-in Promotion 
Rooming-in has been positively correlated in three articles (Abrahams et al., 2007; 
Newman et al., 2015; Short, Gannon, & Abatemarco, 2016). Rooming-in is useful in infants with 
NAS that are transitioned from the NICU to the nursery or that are physiologically stable enough 
to require less monitoring.  The process of rooming-in allows women to stay in the same room 
with their infants after delivery, rather than being placed on a different unit. Rooming-in has 
been shown to reduce pharmacological treatment, length of stay of infants, overall cost, and 
hospital resources. Rooming-in aids in the infants’ transition to extra-uterine life and promotes 
better care from the mother. This approach allows the infant to be discharged in the custody of 
the mother in a timely manner compared to mother-child dyads not involved in rooming-in. 
Inspiring autonomy in women post-partum can be promoted by involving her in the care of her 
infant shortly after birth which is easier if the child is in direct proximity. Rooming-in is an 
important intervention for both the woman and the infant. Infants born with NAS can benefit 
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from multiple family members being present for feeding on demand and immediate soothing of 
the clinical manifestations of NAS.  
 
Pharmacological Interventions 
Pharmacological interventions are often necessary in infants experiencing NAS. Nine 
studies discussed the importance of pharmacological intervention in the treatment regimen for 
infants with NAS (Abdel-Latif et al., 2006; Abrahams et al., 2007; Gottesman, Chang, Feldman, 
& Ziegler, 2018; Isemann, Meinzen-Derr, & Akinbi, 2011; MacVicar, Humphrey, & Forbes-
McKay, 2017; Maguire, Shaffer-Hudkins, Armstrong, & Clark, 2018; Newman et al., 2015; 
Pritham, 2012; Pritham, Paul, & Hayes, 2012). Phenobarbital, methadone, and morphine are 
consistently used in the treatment regimen for infants with NAS exposed to opioids during 
pregnancy, and are used according to a facility’s policy. Other interventions can be used prior to, 
and in conjunction with pharmacological interventions. Benefits and drawbacks of drug therapy 
in infants with NAS should be explained in depth to families. Pharmacological management with 
opioid replacement therapy can reduce the central nervous system irritability that leads to 
disrupted feeding, and therefore poor weight gain. Pharmacological intervention has been 
associated with decreased length of stay, treatment duration, clinical manifestations and overall 
cost.  
 
Non-Pharmacological Interventions 
Non-pharmacological interventions should be explored early in the development of the 
treatment regimen for an infant with NAS to improve physiologic outcomes, such as weight gain. 
Across five separate studies (MacVicar, Humphrey, & Forbes-McKay, 2017; Maguire, Shaffer-
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Hudkins, Armstrong, & Clark, 2018; Maichuk, Zahorodny, & Marshall, 1999; Short, Gannon, & 
Abatemarco, 2016; White-Traut et al., 2002), various interventions are discussed to improve 
physiologic outcomes for infants with NAS. Minimizing external stimuli, maintaining 
temperature control, reducing activity, regulating noise, loose swaddling, limiting exposure to 
light, warm baths, C-positioning, and horizontal rocking are examples of non-pharmacological 
interventions that had positive outcomes for improved feeding and weight gain. Education about 
different methods of consoling infants with NAS to improve length of time during each feeding, 
and how to read feeding cues that are different from NAS symptoms can improve weight gain 
and decrease the amount of time spent in the NICU or facility. Women and families not educated 
about feeding infants with NAS can become easily frustrated and struggle to maintain motivation 
to feed their infants. This can lead to less than optimal weight gain and failure to thrive, 
increased need for health care services, and costly health care.  
Skin to skin contact, chin to cheek support, and ATVV intervention can promote 
improved physiologic outcomes in infants with NAS. Non-pharmacological interventions to 
increase length of time feeding can assist with lowering levels of distress, optimizing weight 
gain, reducing length of stay, and therefore reducing overall cost spent (White-Traut et al., 
2002). 
Length of Stay & Overall Cost 
Nine articles reflect on the interventions previously mentioned, and their effects on 
decreasing length of stay, and therefore, reducing overall cost for families of infants with NAS 
(Abdel-Latif et al., 2006; Abrahams et al., 2007; Gottesman, Chang, Feldman, & Ziegler, 2018; 
Isemann, Meinzen-Derr, & Akinbi, 2011; MacVicar, Humphrey, & Forbes-McKay, 2017; 
Newman et al., 2015; Pritham, 2012; Pritham, Paul, & Hayes, 2012; Short, Gannon, & 
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Abatemarco, 2016). “According to The March of Dimes, the length of an average NICU stay 
hovers at around 13.2 days. That’s an average cost of $39,600, not factoring in the pregnancy 
and birthing costs” (Norsworthy, 2017). Optimizing feeding position and greater nutrient intake 
in an infant with NAS to improve weight gain can reduce length of stay in the NICU. It can also 
provide an opportunity for autonomy to the woman in caring for her infant and less exposure of 
the infant to potential pathogens found in acute care facilities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27 
LIMITATIONS 
Several limitations were noted in this review of literature. Initial search results revealed 
numerous findings on keywords neonatal abstinence syndrome, clinical manifestations, NICU, 
weight gain, feeding, nutrition, breast feeding, CNS disturbances, vomiting, irritability, diarrhea, 
cost, and duration; however, fewer original research articles remained relevant to the purpose of 
this literature review. Search terms were expanded to include keywords symptoms, benefit, high-
calorie formula, in order to provide more relevant search results. Inclusion and exclusion vary 
between studies and are not defined by concrete widespread criteria used across all articles, 
therefore limiting the definitive review of specific topics discussed in this literature review.  
Many studies were limited by the lack of research in a wider drug-regimen including non-
opiate effects with drugs including amphetamines, and cannabinoids (Abdel-Latif et al., 2006; 
Maguire, Shaffer-Hudkins, Armstrong, & Clark, 2018; Maichuk, Zahorodny, & Marshall, 1999; 
Pritham, Paul, & Hayes, 2012; Short, Gannon, & Abatemarco, 2016). The limitation on 
analyzing effects of a wider range of drugs should be taken into consideration, reflecting that 
maternal substance abuse is inclusive of a wide array of narcotics including, but not limited to: 
stimulants, barbiturates, opiates, cocaine, sedatives, marijuana, and nicotine. It is estimated that 
about five percent of pregnant women will use one or more addictive substances throughout their 
pregnancy (“Substance Use in Women”, 2018). With a 300% increase from 1.5 hospital births to 
6 per 1,000 hospital births as of 2013, it is evident that we must take a stand as healthcare 
professionals to educate and provide resources in the community setting (Ko et al., 2016). 
Furthermore, the degree and duration of prenatal narcotic exposure needs to be taken into 
consideration.  A limitation in many studies in this literature review was the varying degree and 
duration of exposure to medications in utero. As previously discussed, NAS is individualized and 
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will present differently amongst infants. Therefore, the varying degrees of narcotic exposure, if 
known, should be recorded and considered when implementing appropriate interventions.  
There are difficulties obtaining information about drug use during pregnancy in suspected 
cases due to the fear of incarceration or lawful repercussions. The limited availability of medical 
records, and accuracy of documentation to exposure history is a limitation that must be taken into 
consideration (Pritham, Paul, & Hayes, 2012). A major limitation in this literature review was 
the essence of self-reporting. Often times, women feel judged by healthcare providers for a 
history of substance abuse, whether drug therapy was taken throughout pregnancy, or not. This 
presents a major challenge for healthcare providers due to the necessity of the data in 
implementing appropriate interventions for infants with NAS. For example, cannabis or 
marijuana is not fully researched on the effects or the health impact during developmental 
milestones of infants in utero. Due to the unreliable nature of self-reporting, the number of 
women using marijuana during pregnancy is unknown, though there has been substantial 
evidence of statistical significance between marijuana smoking throughout pregnancy, and low 
birth weight (“Substance Use in Women”, 2018). Data regarding stimulant use during pregnancy 
and the effects on the neonate are not fully understood. There have been effects linked to low 
birth weight, smaller head circumference, irritability, hyperactivity, tremors, high-pitched cries, 
and excessive sucking at birth (“Substance Use in Women”, 2018) due to stimulant use during 
pregancy. 
Furthermore, pregnant women are not aware of the damage opioid abuse and prescription 
drug therapy during pregnancy can have on the fetus and in some instances the disadvantages to 
the fetus are not clearly defined. A limitation in this literature review dealt with the lack of 
differentiation between legitimate use of an opioid prescription and maternal opioid abuse 
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(Short, Gannon, & Abatemarco, 2016). In-depth information about prescriptive drug regimens 
during pregnancy and the teratogenic effects that can result in fetal deprivation of nutrients are 
unknown for many drugs. There were also limitations in two studies that focused on the lack of 
identification in maternal opioid dependence drug regimens used for treatment, which may have 
influenced length of stay, and overall cost spent for the NAS infants time in NICU (Pritham, 
Paul, & Hayes, 2012; Short, Gannon, & Abatemarco, 2016). Commencement and duration of 
maternal treatment (MMT and BMT) during pregnancy varied greatly, and should also be taken 
into consideration. 
 There was a widespread limitation across articles that used single sites to conduct their 
studies. Additionally, the lack of prospective studies became evident while determining articles 
to utilize in this literature review.  
 Lastly, the use of scoring tools to assess NAS withdrawal severity posed challenges when 
regarding possible subjective observer bias. This variability in the assessment of NAS changes 
implementation of appropriate interventions for infants, and may contribute to greater length of 
stay and overall cost, based on the differing interpretations of the condition. Six articles 
discussed the use of the Finnegan Scoring System, and/or the Neonatal Abstinence Scoring 
System (Abdel-Latif et al., 2006; Gottesman, Chang, Feldman, & Ziegler, 2018; Isemann, 
Meinzen-Derr, & Akinbi, 2011; MacVicar, Humphrey, & Forbes-McKay, 2017; Maichuk, 
Zahorodny, & Marshall, 1999; Newman et al., 2015).  
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Recommendations for Feeding Management to Promote Weight Gain in Infants with NAS  
Implementation of Breastfeeding Promotion 
Breastfeeding practices should be promoted by healthcare professionals so long as no 
outstanding contraindications are present, urine drug screens are negative, and mothers are 
actively participating in methadone maintenance therapy, buprenorphine maintenance therapy, or 
other appropriate and equally substantial therapies (Pritham, Paul, & Hayes, 2012). Studies in 
this literature review have shown that breastfeeding should be encouraged to aid in the reduction 
of clinical manifestations regarding neonatal abstinence syndrome, decreasing the need for 
pharmacological interventions, reducing length of stay, while also optimizing weight gain in 
infants.  
Implementation of Rooming-in Promotion 
Rooming-in, when appropriate, is an intervention that can be explored regarding the 
reduction of clinical manifestations of NAS, and improving weight gain in infants with NAS. 
Furthermore, rooming-in has been associated with greater likelihood of retaining custody of the 
infant, reduction of pharmacological treatment, length of stay, overall cost, and hospital 
resources.  
Implementation of Pharmacological and Non-Pharmacological Interventions 
Pharmacological interventions are often necessary in the plan of care for infants with 
NAS. The use of both pharmacological and non-pharmacological interventions are important in 
reducing clinical manifestations of NAS, and therefore increasing opportunities to optimize 
weight gain. These interventions are also associated with decreased length of stay, treatment 
duration, and overall cost. The use of skin to skin contact, auditory, tactile, visual & vestibular 
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(ATVV) intervention, C-positioning, warm baths, decreased eye contact, and reduced 
environmental stimuli should be used frequently in conjunction with pharmacological treatment.  
Research 
Further research is needed to determine the correlation between dose-related effects of 
prenatal narcotic and stimulant exposure, regarding their effects on NAS, and how they affect 
clinical manifestations displayed by infants, and infant’s ability to feed in different positions for 
weight gain. The effects of non-opiate drugs on infants with NAS is not widely understood. 
Though the rise in opiate use during pregnancy is a serious concern, exploring the gaps in 
research regarding non-opiate drugs use during pregnancy, and their effects on NAS and infant 
feeding and weight gain is of value.  
Though the articles included in this literature review were helpful in identifying current 
challenges in the management of NAS to improve feeding and weight gain, further qualitative 
research from the nurses’ perspective, as well as the perception of the many families, regarding 
infant feeding to promote weight gain would be of value to decreasing length of time and cost. 
The psychosocial stressors of financial duty regarding severity of NAS, and length of stay were 
present in these articles, but should be further explored from a psychological standpoint. 
Additionally, the challenges of self-reporting should be researched further, so that proper 
interventions may be implemented according to not only clinical manifestations present during 
interaction with the pregnant woman, but through quantitative data related to commencement 
during gestational age, type of drug, and duration of use.  
Education 
Successful implement of meaningful feeding interventions to improve weight gain in 
infants with NAS include decreasing the clinical manifestations of NAS, optimize weight gain 
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with a nutrient dense formula or breast-milk, and reducing the need for pharmacological 
treatment. Health care providers are effective in providing communication and consolation 
techniques with not only the infant with NAS, but the families of the infant as well, to promote 
better bonding patterns, which can improve feeding. Families, if present, can be included during 
treatment plans to promote autonomy and to make preparations to care for the infant after 
discharge. There is a need for prevention and resource education regarding maternal substance 
abuse, as well as prescribed drug therapy throughout pregnancy.  
Nursing Practice 
Research findings have many implications for nursing practice. The responsibility of not 
only a nurse, but a healthcare professional is to stay knowledgeable with current evidence-based 
research, and implement the research into their daily practice. It has been proven that nurses who 
are caring for infants who are actively experiencing withdrawal symptoms from neonatal 
abstinence syndrome can reduce clinical manifestations by laying the infant prone for “tummy 
time.” There are many variables to consider when configuring the best feeding practice for infants 
with NAS. Often times, feeding position preference can change daily, or during every intervention 
period. What works one day, may not work the next, and it’s imperative that nurses find the right 
position to soothe the infant, and optimize weight gain. Additionally, there are multiple factors 
regarding the fluctuation of severity of neonatal abstinence syndrome. Medications are often 
titrated, and environmental factors may not remain the same each day. Therefore, the severity of 
NAS can be highly influenced by changes in the environment, and can pose as further challenges 
in managing the positioning and intake of infants with NAS. 
Regarding feeding, the C-position, where the infant is placed on its side, lying on the 
caregiver’s legs, with arms slightly flexed, keeping the head of the infant slightly elevated by 
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crossing one leg over the other has been proven to be helpful in the optimization of weight gain. 
Additionally, while holding the infant, placing the infant in a side-lying position while supporting 
their weight on your chest or stomach, and using chin and cheek support has been especially 
helpful in managing nutritional intake for infants with NAS.  
Conclusion 
Current research regarding breastfeeding promotion, rooming-in, pharmacological and 
non-pharmacological treatments has potential to influence nursing practice in the management of 
feeding positions, nutritional intake, and weight gain in infants with neonatal abstinence 
syndrome. The literature suggests various approaches to feeding techniques are required and can 
benefit the infant and post-partum woman through reduction in the severity of clinical 
manifestations for infants with NAS, reduced length of stay, reduced cost, and improved weight 
gain in infants (Abdel-Latif et al., 2006; Abrahams et al., 2007; Gottesman, Chang, Feldman, & 
Ziegler, 2018; Isemann, Meinzen-Derr, & Akinbi, 2011; MacVicar, Humphrey, & Forbes-
McKay, 2017; Maguire, Shaffer-Hudkins, Armstrong, & Clark, 2018; Newman et al., 2015; 
Pritham, 2012; Pritham, Paul, & Hayes, 2012; Short, Gannon, & Abatemarco, 2016). However, 
the correlation between dose-related effects of both opiate and non-opiate exposure in utero on 
optimization of weight gain through improved feeding techniques and nutrient intake is unclear. 
Though the reduction of clinical manifestations can improve breastfeeding promotion, rooming-
in, pharmacological and non-pharmacological interventions has been established in the literature, 
further research must be conducted to fill the gaps of knowledge on subtopics that aren’t fully 
understood. The use of these interventions has been associated with improved health-related 
outcomes, and reduced clinical manifestations, leading to optimized weight gain in infants with 
NAS.  
 
 
 
 34 
APPENDIX A: FIGURE 
  
 
 
 
 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Search Terms = Neonatal abstinence syndrome*, clinical manifestations*, symptoms*, benefit*, 
NICU*, weight gain*, feeding*, nutrition*, high-calorie formula*, breast feeding*, CNS disturbances*, 
vomiting*, irritability*, diarrhea*, cost*, and duration* 
Limiters = English language, peer-reviewed, published between 1995-2018 
 
Figure 1: Selection Method of Literature  
Potentially relevant citations identified after screening of databases  
(ERIC, CINAHL, PsycINFO, MEDLINE) 
(n = 2,461) 
Citations excluded due to not 
meeting the inclusion criteria 
(n = 2,441) 
Studies retrieved for more detailed review 
(n = 20) 
Studies excluded after a more 
detailed review due to not 
completely meeting inclusion 
criteria (n = 8) 
Relevant studies included 
which met all of the 
inclusion criteria 
(n =11) 
Additional studies reviewed and selected for 
use (by hand searching credible reference 
citations) meeting inclusion criteria making 
total n = 12 for review 
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Table 1: Table of Evidence 
 
Author(s) 
Year  
Location 
Study Design 
and Purpose 
Sample 
Size 
Intervention 
Protocol 
Screening 
Measures 
Outcome Measures Key Findings and  
Limitations 
Abdel-Latif 
et al. (2006) 
Australia 
 
 
 
 
Retrospective 
cohort study 
 
The purpose 
of this study 
was to assess 
the effects of 
breast milk 
feeding on 
the severity 
of neonatal 
abstinence 
syndrome 
(NAS) in a 
population of 
infants of 
drug-
dependent 
mothers who 
were at risk 
of NAS.  
 
 
n=190 
 
Breast milk 
n=85 
 
Formula 
n=105 
Infants were 
assessed with the 
Finnegan objective 
Scoring System 
before the first feed, 
and were assessed 
before every feed 
for the duration of 
admission.  
 
Swaddling, frequent 
feeds, and nursing in 
quiet environments 
were applied from 
birth.  
 
Pharmacological 
treatment began if 
the Finnegan score 
exceeded 8 on 2 
occasions or was 
>10 on 1 occasion. 
 
Morphine was 
started at 0.5 mg/kg 
per day in 4 divided 
doses for polydrug 
and opiate-exposed 
infants and 
increased or 
decreased 10% 
every 2-3 days to 
maintain an average 
This study included 
infants of drug 
dependent mothers 
admitted to a local 
Australian hospital, 
between 1998 and 
2004.  
 
190 total 
consecutive 
charts were 
reviewed for 
maternal and infant 
data for this study. 
 
In this specific 
hospital, infants 
born to drug-
dependent mothers 
were nursed with 
their mothers in the 
postnatal wards 
unless there were 
medical or social 
contraindications.  
 
All mothers were 
encouraged to 
breastfeed or 
express their milk 
for bottle or gavage 
feedings unless it 
was contraindicated. 
The mean Finnegan 
scores for the first 9 
days of life were 
considerably lower in 
breast milk infants.  
 
The median time to 
withdrawal occurred 
considerably 
later in breast milk 
infants in comparison 
to the 
formula group (10 vs 
3 days; P < .001). 
 
Breast milk infants 
were less likely to 
require 
pharmacologic 
treatment for 
withdrawal (59.0% vs 
79.0%, respectively    
P < .001).  
 
6 (7.0%) infants from 
the breast milk group, 
and 18 (17.1%) from 
the formula group 
required 
phenobarbital in 
addition to the 
morphine to control 
NAS.  
 
Among 190 infants born to drug-
dependent mothers in New South Wales, 
breast milk significantly reduced the 
severity of NAS and reduced the length of 
hospital stay. The length of stay 
among infants who were breastfed was 
14.7 days compared to 19.1 days for non-
breastfed infants (p = 0.049). 
 
The Finnegan scores for the formula 
group were consistently higher in the 
groups of premature infants and those 
who were exposed to polydrug, 
methadone, opioid, or maternal 
methadone use >80 mg/kg per day. There 
was no difference in Finnegan scores 
between breastfed infants and those given 
breast milk by bottle or gavage tube 
within the breast milk group.  
 
Overall treatment in the breast milk group 
was 20 days less than those in the formula 
group. The maximum amount of 
morphine was lower in the breast milk 
group. Breast milk was found to be 
independently associated with a lessened 
need for pharmacologic treatment for 
NAS. 
 
Limitations: The majority of the infants in 
the study were exposed to opiates, and 
only a few were exposed to stimulants 
such as cocaine and amphetamines. No 
reliable system has been found for 
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Finnegan score of 
<8.  
 
Phenobarbital was 
given to polydrug 
opiate-exposed 
infants in addition to 
morphine if 
symptoms were 
uncontrolled.  
accurately assessing non-opiate effects, 
resulting from those such as cocaine, 
cannabinoids, and amphetamines.  
Abrahams et 
al. (2007) 
Canada 
 
 
 
 
Retrospective 
cohort study 
 
The purpose 
of this study 
was to 
evaluate the 
effect of 
rooming-in 
(rather than 
standard 
nursery care) 
on the 
incidence and 
severity of 
neonatal 
abstinence 
syndrome 
among 
opioid-
exposed 
newborns and 
on the 
proportion of 
mothers who 
retain custody 
of their 
babies at 
n=106 
Total 
sample of 
methadone 
or heroin 
using 
women 
 
n=32 
Rooming-in 
mothers  
 
n=38  
Mothers 
who gave 
birth at a 
local 
hospital 
before the 
rooming-in 
program 
 
n=36  
Mothers 
who 
reported 
use of 
heroin or 
methadone, 
A rooming-in care 
program. Routine 
care, instruction by 
nursing staff on how 
to care for the baby 
and how to identify 
symptoms of NAS. 
Parenting skills and 
symptoms of NAS 
were assessed and 
observed. Mothers 
were consulted 
about their 
observation of NAS 
in their newborns.  
 
Before rooming-in 
group: The same 
approach to 
obstetric care as the 
study group, with no 
rooming-in. Babies 
were kept in a 
nursery, separate 
from their mothers 
during the first week 
of life.  
 
This study included 
women referred by a 
local hospital who 
were identified as 
users of illicit drugs 
such as heroin or 
methadone, or 
whose newborns 
were identified as 
showing symptoms 
of opiate 
withdrawal.  
 
Among women who 
had had children 
previously, fewer in 
the rooming-in group 
had retained custody 
of at least 1 child 
(7.7%) than in the 
local hospital 
comparison group 
(15.6%) or the 
additional local 
hospital group 
(22.6%). 
 
More women in the 
rooming-in group 
were breastfeeding 
(62.5%) than women 
in the BCWH group 
(7.9%) or the Surrey 
group (11.1%) were. 
 
Newborn length of 
stay in hospital was 
significantly shorter 
in the rooming-in 
group compared with 
the BCWH 
comparison group (β-
Rooming-in was associated with 
substantially reduced rates of newborn 
treatment with morphine, length of 
morphine treatment, vomiting, admission 
to a level II nursery, and length of stay in 
hospital. Mothers who roomed in were 
much more likely to retain custody of 
their newborns. 
 
Newborns who roomed-in at BCWH were 
much more likely to be discharged in the 
custody of their mothers than infants in 
the other groups.  
 
Overall, rooming-in is associated with 
easing a newborns’ transition and 
promote better care from the mother. 
 
Limitations:  
The subjects were non-randomly 
allocated. The subjects didn’t choose their 
study groups. The research cannot 
exclude the possibility that mothers of 
newborns who didn’t show signs of NAS 
weren’t included in this study. The 
mother-infant dyad was included if the 
newborn showed signs of NAS within the 
first few days of life.   
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hospital 
discharge.  
or whose 
babies were 
admitted to 
a level II 
observation 
nursery at 
an 
additional 
local 
hospital. 
Heroin/methadone 
use &/or 
observation nursery: 
Babies were kept in 
a nursery, separate 
from their mothers 
during the first week 
of life.  
 
Morphine was 
prescribed as needed 
for all 3 groups, and 
was titrated to 
control symptoms.  
coefficient for cohort 
membership 1.17, 
standard error 
0.46, P = .01), 
adjusted for maternal 
methadone dose at 
delivery and 
involvement of the 
father. 
 
Gottesman et 
al. (2018) 
United States 
of America 
 
Case Study 
 
The purpose 
of this study 
was to 
expand the 
research on a 
vulnerable 
population in 
regard to 
neonatal 
abstinence 
syndrome and 
nutritional 
challenges 
many 
neonates 
affected by 
NAS face.  
n=1 infant Baby N was started 
on a transitional 
formula initially. 
Baby N received a 
full nutrition 
assessment 
(recommendation 
for oral feeding 
modifications, 
adjustment of 
formula goal rate, 
and evaluation of 
growth patterns) on 
day 2 of life, and 
was reassessed 
every 3-5 days while 
he remained in the 
intermediate 
nursery.  
 
Monitoring of 
tolerance to 
feedings, daily 
weight gain, 
tracking of growth 
Baby N was 
admitted to an 
intermediate nursery 
in July of 2016, born 
at 38 weeks and 4 
days’ gestation and 
was delivered via C-
section. Apgar 
scores at 1 minute 
and 5 minutes were 
recorded, and were 
8 and 9 respectively.  
 
Baby N displayed 
signs and symptoms 
of NAS including: 
tremors, jitteriness, 
and high-pitched 
cries postnatally.  
 
Baby N’s 
anthropometric 
measurements at 
birth were a weight 
of 2355 g, length of 
Each month, Baby N 
experienced a change 
in feeding regimen to 
lessen the severity of 
NAS, and to meet 
goals for 
anthropometric 
measurements, which 
were additionally 
recorded each month.  
 
Initially, Baby N 
started on a 
transitional formula. 
At month 2, he 
switched to a 20-
calorie per ounce 
term formula, which 
lead to a weight gain 
of 36.2g/d. He slowly 
began to wean from 
phenobarbital and 
morphine. However, 
he re-exhibited signs 
of withdrawal 
The experience of Baby N displays the 
challenges that many infants with NAS 
face. He was small for gestational age, 
had poor growth, was irritable at meal 
times, had an increased length of stay in 
the hospital, and showed poor growth.  
 
Though Baby N’s formula goals were 
continually adjusted to promote better 
weight gain, total gains in length, head 
circumference, and weight remained less 
than desired.  
 
Breastfeeding has shown to be best for 
the infant with NAS. Breastfeeding has 
been associated with clinical outcomes 
through reductions in the severity of 
NAS, duration of treatment, and overall 
length of stay. The benefits of 
breastfeeding for this vulnerable group 
outweigh any of the potential risks, 
granted that the mother is on a stable dose 
of methadone or buprenorphine, and is 
actively involved in an opioid 
management program. 
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velocity goals, 
weekly head 
circumference and 
length 
measurements, 
monitoring changes 
in electrolytes, and 
implementation of 
nutrition-related 
medications 
(vitamins, and 
minerals).  
 
Each month, feeding 
regimens were 
changed, 
anthropometric 
measurements were 
recorded, Baby N 
was continually 
assessed by the 
Finnegan scoring 
system, and 
pharmacological 
regimens were 
added in 
accordingly.  
 
Morphine and 
phenobarbital were 
ordered, 
administered, and 
titrated based on 
Finnegan scores.  
46.5 cm, and head 
circumference of 
32.5 cm.  
through 
hyperirritability and 
high-pitched cries, 
therefore morphine 
and phenobarbital 
were titrated 
accordingly. At 
month 3, Baby N 
stayed on the 20-
calorie per ounce 
term formula, and 
had a weight gain of 
25 g/d. He continued 
to show signs of 
withdrawal. At month 
4, Baby N continued 
to receive 20-calorie 
per ounce term 
formula. He gained 
25.7g/d, and 
Finnegan scores 
remained elevated. 
Phenobarbital was 
titrated, methadone 
was added to support 
withdrawal, and 
morphine was 
removed. At month 5, 
Baby N transitioned 
to a 24-calorie per 
ounce preterm 
formula to promote 
weight gain. He had a 
weight gain of 11.5 
g/d. Finnegan scores 
were decreasing, and 
phenobarbital and 
methadone were 
titrated. At month 6, 
 
Limitations in NAS research:  
Few studies have addressed nutrition 
interventions for infants with NAS when 
breastfeeding is not an option. There are 
limited prospective studies or clinical 
trials available to base NAS nutritional 
management decisions. 
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Baby N remained on 
the 24-calorie per 
ounce term formula 
with iron. He had a 
weight gain of 7.4 
g/d. Finnegan scores 
were low, and 
methadone was 
discontinued.  
Isemann et al. 
(2011) 
United States 
of America 
 
Retrospective 
cohort study 
 
The purpose 
of this study 
was to 
identify 
maternal and 
neonatal 
factors that 
impact 
response to 
methadone 
therapy for 
neonatal 
abstinence 
syndrome. 
n=142 total 
infants 
 
n=128 
infants’ 
post-
exclusion 
 
n=36 
preterm 
infants  
 
n=92 term 
infants 
 
Pharmacotherapy 
for opiate 
withdrawal to 
identify factors 
associated with 
favorable response 
to methadone 
therapy.  
 
Infants were scored 
with the Finnegan 
Scoring System. 
Infants received 
methadone per 
protocol if signs of 
NAS continued. 
Post-non-
pharmacologic 
management 
(swaddling, minimal 
tactile stimulation, 
dimmed lighting and 
frequent feeding).  
 
Methadone therapy 
started at 0.1 mg kg 
orally every 4 hours, 
following two 
consecutive 
Finnegan scores 
Inclusion: Most 
infants (82%) were 
born to mothers that 
received prenatal 
care. All patients 
were managed with 
methadone therapy. 
Other infants were 
born to mothers with 
a history of 
dependence on 
opiates or had urine 
drug screen positive 
for opiates. All 
newborn infants 
who were treated 
with at least one 
dose of methadone 
were eligible.  
 
Exclusion: If infants 
had no 
documentation of 
methadone on their 
medical record, if 
opiates were 
administered before 
initiating methadone 
protocol, if the 
methadone protocol 
Infants that required 
adjunctive therapy 
with phenobarbital 
were born of mothers 
on higher doses of 
methadone (median 
90 (0 to 150) vs 60 (0 
to 160) mg per day, 
P.0.04) and they had 
longer LOS (median 
24.5 (12 to 93) vs 
13.0 (3 to 43) days, 
P<0.0001) compared 
with infants managed 
with methadone 
therapy alone.  
 
Methadone therapy 
was initiated at a later 
time (P = 0.04), was 
accelerated more 
frequently (P<0.01) 
and was 
supplemented with 
phenobarbital less 
frequently (P=0.002) 
in preterm infants 
compared with term 
infants. 
 
There were no significant differences in 
the length of stay between neonates 
exposed to methadone in utero compared 
with infants that were additionally 
exposed to other classes of drugs such as 
benzodiazepines (n = 17), barbiturates (n 
= 7), cocaine (n = 23), selective serotonin 
reuptake inhibitors (n = 17), marijuana (n 
= 12), additional opiates (n = 29) or 
tobacco (n = 98). 
 
Maternal breast milk feedings were 
associated with shorter median duration 
of methadone therapy in both term and 
preterm infants. 
 
Compared with infants who were 
formula-fed, consumption of maternal 
breast milk was associated with shorter 
length of stay (median 12.5 (3 to 51) vs 
18.5 (9 to 43) days, P= 0.01). 
 
Limitations:  
Incomplete collection of data from 
medical records.  
 
The use of the Finnegan Scoring System 
to assess NAS was designed for term 
infants, and may not be sensitive in the 
assessment of NAS in preterm infants.  
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above 8. An eight-
step tapered dosing 
regimen was 
followed, which was 
guided by Finnegan 
scores assessed 
every 4 hours.  
 
If doses or steps in 
the eight-step 
tapered dosing 
regimen were 
skipped, infants 
were seen as having 
accelerated the 
taper. Infants unable 
to progress with 
continuously 
elevated Finnegan 
scores were seen as 
non-responders, and 
were additionally 
treated with 
phenobarbital at 10 
mg/kg orally every 
12 hours.  
for initial dosing 
was not adhered to, 
if the infant was 
transferred to 
another hospital, or 
if the infant perished 
before the 
completion of 
methadone tapering.  
Maternal methadone 
maintenance dose 
during pregnancy 
correlated with 
overall length of stay 
(P = 0.009). There 
was an inverse 
correlation between 
the amount of 
mother’s breast milk 
ingested and length 
of stay (B = -0.03, P 
= 0.02). 
 
 
 
Possible bias in initiating MBM therapy 
at lower doses, and more aggressive 
weaning of infants fed MBM, which may 
have contributed to earlier discharge.  
 
 
MacVicar et 
al. (2017) 
United 
Kingdom  
Mixed-
methods pilot 
study 
 
The purpose 
of this study 
was to 
evaluate the 
feasibility 
of the 
intervention 
and to assess 
whether a 
n=53 total 
assessed for 
eligibility 
 
n=14 total 
neonates’ 
post-
exclusion 
 
n=7 
intervention 
neonates  
 
The intervention 
group received 
support based on 
practical 
breastfeeding 
advice, promotion of 
maternal self-
efficacy through 
encouragement and 
persuasion, and 
provision of 
neonatal self-
consolation 
The subjects in this 
study were recruited 
from a combined 
specialist obstetric 
or substance abuse 
clinic.  
 
Inclusion criteria 
included: Opioid 
substation 
medication therapy 
during pregnancy, 
intention to 
On the fifth postnatal 
day, 100% (7 of 7) of 
the intervention 
group was still 
breastfeeding 
compared with 57% 
(4 of 7) of control 
participants.  
 
Of the intervention 
group, 28% (2 of 7) 
required 
pharmacotherapy for 
Questionnaire: Thematic analysis 
generated 5 key themes relating to 
breastfeeding support and substance 
exposure: (1) breastfeeding skill and 
knowledge, (2) psychological factors, (3) 
person-centered approach, (4) 
environmental modifications, and (5) 
postnatal experience on breastfeeding.  
 
There was a demonstrated trend for 
continued breastfeeding on the fifth 
postnatal day, and intervention 
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future 
adequately 
powered 
randomized 
controlled 
trial was 
warranted. 
n=7 control 
neonates 
techniques within a 
low-stimuli 
environment. A 
scheduled session 
with a support 
worker was 
included, where 
collaboration 
resulted between 
mothers and support 
workers to identify 
breastfeeding 
barriers, 
opportunities to 
problem solve, and 
set individualized, 
family-centered 
goals. Additionally, 
environmental 
modifications took 
place, such as 
minimizing external 
stimuli through 
temperature control, 
reduced activity, and 
regulated noise. 
 
The infants were 
nursed in a shielded 
cot and canopy to 
limit exposure to 
light. The mother 
was provided and 
instructed with 
consolation 
techniques including 
non-nutritive 
sucking, and loose 
swaddling for self-
breastfeed, > 36 
weeks’ gestation, 
and over 16 years of 
age.  
 
Exclusion criteria 
included: Those 
who were HIV 
positive, ongoing 
illicit psychoactive 
drug or alcohol use, 
and had a child 
removal order in 
force.  
severe withdrawal 
compared with 57% 
(4 of 7) in the control 
group. 
 
The intervention 
group also had a 
shorter duration of 
hospitalization 
(mean 10.5 days) 
than the control 
group (mean 
19.4 days). 
Collectively breastfed 
infants were less 
likely to require 
pharmacotherapy (3 
of 11 breastfeeding 
vs 3 of 3 formula 
feeding).  
 
 
participants reported increased 
breastfeeding confidence and satisfaction.  
 
The intervention group had higher 
breastfeeding rates, and higher confidence 
in terms of breastfeeding ability than 
those in the control group.  
 
Breastfed infants were less likely to 
require pharmacotherapy for neonatal 
withdrawal and had a shorter hospital stay 
than infants who were formula-fed (10.8 
and 30.0 days, respectively). 
 
Maternal experience of health care 
practices, attitudes, and postnatal 
environment influenced their perceptions 
of breastfeeding support. 
 
Breastfed infants displayed a less 
significant course of withdrawal.  
 
Limitations:  
This study used a single site only, and 
there was homogeneity of the population. 
The research may not be representative of 
other locations, other than Scotland, 
where service in health care differs. 
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soothing purposes 
for the infant.  
 
This intervention 
lasted from birth up 
to and including the 
fifth postnatal day.  
 
Severity of neonatal 
withdrawal was 
assessed every 4-6 
hours with the 
Finnegan Scoring 
System.  
Maguire et al. 
(2018) 
United States 
of America 
Focus group 
methodology  
  
The purpose 
of this study 
was to learn 
how 
caregivers 
who are 
expert in 
feeding 
infants with 
neonatal 
abstinence 
syndrome 
(NAS) 
successfully 
feed these 
infants during 
withdrawal.  
n=12 total 
 
n=10 RNs 
 
n=2 
occupationa
l therapists 
Information was 
gathered from 12 
participants 
including NICU 
nurses and speech 
therapists, through 
two separate focus 
group discussions.  
 
 
Data were collected 
from participants 
working in three 
regional hospitals 
with Level III 
NICUs.  
 
NICU nurses, 
occupational 
therapists, and 
speech therapists 
who self-identified 
as experienced in 
feeding infants with 
NAS were included.  
 
Four participants 
from each hospital.  
 
All were female, 
most (11) worked 
full time. Their ages 
ranged from 31 to 
65 years, years 
working in the 
There were 4 
overarching themes, 
and 8 subthemes that 
the data resulted in. 
 
Overarching themes:  
(1) Optimal 
medication 
management
. 
(2) Follow the 
baby’s cues 
and be 
flexible with 
techniques. 
(3) Calm and 
comfortable.  
(4) Nurture the 
relationship.  
 
Subthemes:  
(1) Follow the baby’s 
cues 
(2) Flexibility with 
techniques 
Results showed that pharmacologic 
management with opioid replacement 
therapy is very important, because it 
dampens the central nervous system 
irritability that leads to disrupted feeding. 
 
Sucking behaviors were described as 
being disorganized and frantic before 
optimal medication management was 
achieved. Nurses did not expect to be 
successful in feeding infants with NAS 
whose signs were not well under control, 
and collaborated with the medical team to 
re-evaluate the plan of care to achieve 
these goals.  
 
Neurobehavioral organization plays an 
important role in successful feeding.  
 
Informants reported that the baby is often 
not ready to feed when he is picked up, so 
nursing assessment of feeding cues was 
crucial for success. 
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NICU ranged from 
2-43, and years in 
their profession 
ranged from 2-43.  
(3) Calm the 
caregiver  
(4) A calm and 
comfortable baby 
before and during 
feeding. 
(5) Encourage 
caregivers to be 
there.  
(6) Provide 
continuity in 
caregiving. 
(7) Build parent’s 
confidence. 
(8) Develop trust and 
avoid judgmental 
attitudes.  
A technique that works one day may not 
work the next day, so continued trial and 
error is needed. 
 
The informants strongly believed that 
anxiety in a caregiver could be felt by the 
infant, who was likely to react negatively. 
 
Swaddling and decreasing environmental 
stimulation help calm the infant and keep 
him comfortable. Swaddling is one of the 
few nonpharmacologic interventions that 
has been reported to be effective in 
infants with NAS to reduce crying. 
Swaddling has been known to decrease 
startles and sleep arousals, which leads to 
an increase in sleep time, and continuity.  
 
Informants also talked about an 
intervention called the C position they 
adapted for feeding. The infant is placed 
on his side lying on the informants’ legs 
and arms slightly flexed, keeping the head 
of the infant slightly elevated by crossing 
one leg over the other.  
 
Warm baths have been used to calm the 
infant, whereas others reported that they 
start by helping the infant to burp. 
 
Most informants reported that they try all 
available nipples until they find the one 
that works the best for the infant, and 
most reported using chin and cheek 
support as needed. Informants used their 
gloved finger to find the “sweet spot” on 
the palate that helped infants form a good 
suck.  
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Informants emphasized the importance of 
vertical versus horizontal rocking to calm 
the infant. 
 
Some informants reported that they often 
bottle feed with the infant facing away 
from them when the infant cannot tolerate 
eye-to-eye contact, to decrease 
stimulation associated with eye contact, 
and is often successful if the infant opens 
his eyes. 
 
Mothers were encouraged to nurture the 
relationship by being available for as 
many feedings as possible. Mothers were 
encouraged to learn infant cues and how 
their infant responds to different 
interventions. 
 
Limitations:  
Research needs to include more 
information on managing a wider range 
of street drugs.  
Maichuk et 
al. (1999)  
United States 
of America  
Randomized 
to 
intervention 
 
The purpose 
of this study 
was to test 
the 
hypothesis 
that highly 
fretful, 
narcotic-
withdrawing 
neonates 
experience 
less distress 
n=48 total 
 
n=25 
prone-lying 
infants 
 
n=23 
supine-
lying 
infants 
Subjects in this 
study were assessed 
for withdrawal 
severity with the 
Neonatal Abstinence 
Scoring System 
(NASS), and 
through daily caloric 
intake. 
 
Infants showing 
initial signs of 
withdrawal (2 
successive NASS 
scores of ≥ 5) were 
randomly assigned 
Subjects were 
recruited through 
admissions from an 
Intermediate Care 
Nursery in New 
Jersey. All subjects 
had urine toxicology 
findings that were 
positive for heroin 
and/or methadone.  
 
Exclusion: Neonates 
with sepsis, 
congenital 
anomalies, 
respiratory disease, 
Mean caloric intake 
was compared 
between groups by 
the paired t-test. 
Significance was set 
at p <0.05.  
 
Supine-lying, 
narcotic-withdrawing 
infants had 
significantly higher 
peak withdrawal 
severity (NASS) 
scores (13.17 ± 2.03) 
compared with those 
in the prone group 
Even highly irritable infants 
can enjoy a significant reduction in 
distress by being laid prone. 
 
Infants experiencing withdrawal showed 
significantly lower levels of distress and 
lower withdrawal scores when 
laid face down (prone) compared with 
similar infants kept face up (supine). 
 
The difference (30%) between the prone- 
and supine- lying groups was clinically 
significant and was matched by a 
symmetrical increase in feeding by 
supine-lying newborns (30%). 
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in a prone-
lying position 
than 
comparable, 
supine-lying 
neonates.  
to the prone (n = 25) 
or supine-lying (n = 
23) condition. 
 
Infants in the prone 
group were 
swaddled and laid 
belly down for 
sleep, while infants 
in the supine group 
were swaddled and 
laid on their backs. 
 
Per usual practice, 
subjects were fed 
every 3 to 4 hours, 
≤800 calories per 
24 hours. Caloric 
intake was recorded 
at each feeding. 
Infant weight 
was recorded daily 
at 8:00 AM. 
Subjects’ 
withdrawal severity 
was assessed 
by standard 
administration of the 
NASS every 2 or 4 
hours, depending 
on time from onset 
of withdrawal. 
 
Caloric intake was 
summed on a 24-
hour basis and 
divided by the daily 
weight (cal/kg per 
24 hours). Subjects’ 
metabolic disorder, 
gastroesophageal 
reflux, and 
intraventricular 
hemorrhage.  
(10.52 ± 2.08); p < 
0.0001. 
 
Mean NASS scores 
were also 
significantly higher 
in the supine-lying 
group (7.60 ± 0.70) 
compared with the 
prone-lying group 
(5.11 ± 0.64); p < 
0.0001.  
 
Supine-lying subjects 
had higher 
mean caloric intake 
(133 ± 11.2 cal/kg 
per 24 hours) than 
prone-lying 
neonates (100 ± 9.4 
cal/kg per 24 hours), 
a significant 
difference (p <0.001).  
 
There were no 
episodes of apnea, 
aspiration, or 
seizures. 
 
 
Limitations:  
This study was predestined by the use of 
the NASS to assess withdrawal severity. 
As designed and administered, the NASS 
does not allow for case-blind evaluation 
of neonatal withdrawal. In consideration 
that withdrawal scoring would be 
conducted by the nurses involved in an 
affected infant’s care, the NASS 
introduces the possibility of observer 
bias. 
 
The dose-related effects of prenatal 
narcotic and stimulant exposure on 
neonatal distress was beyond the scope of 
this study. The degree of prenatal narcotic 
and cocaine exposure regarding the 
infants in this study was not quantified. 
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mean and peak 
NASS scores, 
caloric intake, and 
rate of daily weight 
gain were 
determined.   
Newman et 
al. (2015)  
Canada 
Case series 
 
The purpose 
of this study 
was to 
implement a 
rooming-in 
program to 
support close 
uninterrupted 
contact 
between 
opioid-
dependent 
women and 
their infants 
in order to 
decrease the 
severity of 
NAS scores, 
lessen the 
need for 
pharmacother
apy, and 
shorten 
hospital stays. 
n = 24  
NICU 
group 
 
 
n = 21 
rooming-in 
group 
 
Opioid-dependent 
pregnant women 
were assessed 
before giving birth, 
and were provided 
with education and 
support.  
 
Psychosocial issues 
were addressed in 
collaboration with a 
community program 
developed to 
support addicted 
mothers. The 
mother-infant dyad 
was admitted 
postpartum to a 
private room and 
attended by nurses 
trained in Finnegan 
scoring.  
 
Infants remained 
with their mothers 
unless persistently 
elevated Finnegan 
scores deemed it 
necessary for 
transfer to neonatal 
intensive care units 
for commencement 
of pharmacotherapy. 
Inclusion:  
Women in chronic 
opioid therapy, who 
delivered single full-
term infants who 
were not 
apprehended by 
child protection 
services.  
 
Exclusion:  
Women whose 
infants were 
apprehended at birth 
by child protective 
services.  
 
The requirement for 
oral morphine 
therapy for the 
neonates in the 
rooming-in cohort 
was significantly 
lower than those 
admitted directly to 
the NICU (3 of 21 
[14.3%] vs 20 of 24 
[83.3%]; P < .001).  
 
The mean (SD) 
length of stay was 
also significantly 
shorter among those 
in the rooming-in 
cohort (7.9 [7.8] days 
vs 24.8 [15.6] days; P 
< .001).  
Women who participated in the rooming-
in program completed a survey after 
discharge. Anonymous responses were 
obtained from 14 of the 21 participating 
women. On a 5-point scale (1= least 
satisfied, 5 = most satisfied), 100% of 
women rated their overall experience as a 
4 or higher and 86% reported 
breastfeeding their infants for an average 
duration of 2.5 months.  
 
A decrease in the need for 
pharmacotherapy was shown, from 88.3% 
of infants receiving usual care in the 
NICU to only 14.3% of those rooming-in. 
 
Rooming-in could potentially reduce bed 
use and save hospital resources, while 
preventing patients from dealing with 
negative psychosocial stressors.  
 
The length of stay for subjects in this 
study decreased from 24.8 to 7.9 days.  
 
With the implementation of this program, 
a multidisciplinary team had taken the 
approach of permitting rooming-in for 
infants who were born to opioid-
dependent women, rather than sending 
them straight to the NICU. Additionally, 
NICU admission was resorted to only if 
pharmacotherapy was required. Within 
the first year of implementation, this 
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program resulted in decreased length of 
stay, and decreased need for 
pharmacotherapy, while mothers 
favorably rated their experience.  
 
Limitations: The NAS scoring tool that 
was used to quantify withdrawal severity 
somewhat relies on subjective judgement, 
and might contribute to a possible source 
of bias.   
Pritham 
(2012)  
United States 
of America  
 
Retrospective 
study 
 
The purpose 
of this study 
was to 
examine the 
effect of 
infant feeding 
methods on 
neonatal 
abstinence 
syndrome.    
n=152 total 
 
n=136 
opioid-
dependent 
pregnant 
women on 
methadone 
maintenanc
e therapy 
(MMT) 
 
n=16 
opioid-
dependent 
pregnant 
women on 
buprenorph
ine 
maintenanc
e therapy 
(BMT). 
Electronic medical 
records of all 
opioid-dependent 
women who were on 
methadone 
maintenance therapy 
(n=136) or 
buprenorphine 
therapy (n=16) 
during pregnancy, 
and their neonates. 
were reviewed.  
 
  
Inclusion:  
Women on 
methadone 
maintenance therapy 
(n=136) or 
buprenorphine 
maintenance therapy 
(n=16) who labored 
and delivered at a 
hospital in Maine, or 
at an outlying 
community hospital 
during the same 
time-period and 
whose neonates 
were directly 
admitted to the 
Neonatal Intensive 
Care Unit at the 
hospital in Maine 
were used for the 
study.  
 
Exclusion:  
Opioid-dependent 
women not on 
prescribed 
replacement therapy 
with methadone 
Exposed neonates 
receiving neonatal 
abstinence syndrome 
treatment either 
through receiving 
methadone 
maintenance therapy 
or buprenorphine 
maintenance therapy 
who were also 
breastfed began first 
line therapy with 
phenobarbital 1.1 
days later (p=0.008_ 
and their length of 
stay was shorter by 
9.4 days p= .016) as 
compared to formula-
fed neonates or 
neonates who 
received formula and 
breast milk. 
Infant feeding method did not predict 
length of stay for neonatal abstinence 
syndrome.  
 
However, there were statistically 
significant differences between infants 
who were formula-fed and infants who 
were breastfeed in relation to the 
commencement of pharmacologic 
treatment such as phenobarbital for 
neonatal abstinence syndrome. 
 
The three infant feeding methods 
included in this study (formula, breast and 
mixed formula and breast) revealed 
significant differences in neonatal 
abstinence syndrome treatment between 
formula, and breastfed infants but not 
between the formula-fed infants and 
infants fed a mixture of formula and 
breastmilk.   
 
Overall, opioid-dependent women who 
are actively participating in methadone or 
buprenorphine maintenance therapy 
should be encouraged to breastfeed, so 
long as there are no contraindications 
present.  
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maintenance therapy 
or buprenorphine 
maintenance therapy 
were excluded from 
the study. 
 
Neonates less than 
28 weeks’ gestation 
were excluded 
(n=2). The ability of 
the placenta to 
metabolize 
methadone or store 
buprenorphine prior 
to the third trimester 
is not yet fully 
understood.  
Pritham et al., 
(2012)  
United States 
of America 
Retrospective 
descriptive 
study  
 
The purpose 
of this study 
was to 
examine 
opioid 
replacement 
therapy in 
pregnancy 
and maternal 
effects on 
neonatal 
outcomes 
including 
length of 
hospital stay 
for neonatal 
abstinence 
syndrome. 
n=152 total  
 
n=136 
opioid-
dependent 
pregnant 
women on 
methadone 
maintenanc
e therapy 
(MMT) 
 
n=16 
opioid-
dependent 
pregnant 
women on 
buprenorph
ine 
maintenanc
e therapy 
(BMT). 
A retrospective 
chart review was 
conducted of 
medical records for 
opioid-dependent 
pregnant women on 
MMT or BMT and 
their newborns 
delivered between 
January 1, 2005 and 
December 31, 2007. 
Inclusion:  
Women on 
methadone 
maintenance therapy 
(n=136) or 
buprenorphine 
maintenance therapy 
(n=16) who labored 
and delivered at a 
hospital in Maine, or 
at an outlying 
community hospital 
during the same 
time-period and 
whose neonates 
were directly 
admitted to the 
Neonatal Intensive 
Care Unit at the 
hospital in Maine, 
were used for the 
study.  
Data analysis was 
generated using the 
Statistical Package 
for the Social 
Sciences version 19.  
 
The model examined 
variables 
hypothesized to 
affect length of stay, 
such as: maternal 
methadone dose, 
smoking, SSRIs, 
benzodiazepines, 
alcohol, other 
opioids, and 
marijuana. In 
addition, infant 
feeding method was 
added because of the 
association with 
length of stay in other 
Maternal:  
The mean maternal age was 25.3 years 
(standard deviation [SD] 3.9, range 18-
37).  
 
The demographic characteristics of the 
two groups of women, those on 
methadone, and those on buprenorphine, 
were similar for age, gravidity, parity, 
gestational age at first prenatal visit, 
number of prenatal visits, reported use of 
tobacco, alcohol, and marijuana, and 
documentation of prescribed SSRIs 
and/or illicit use of benzodiazepines and 
other opioids.  
 
Neonates:  
The MMT group had significantly smaller 
head circumference (p <.03). There were 
also differences by group in size for 
gestational age (p <.03) with the MMT 
group showing more smaller for 
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Exclusion:  
Opioid-dependent 
women not on 
prescribed 
replacement therapy 
with methadone 
maintenance therapy 
or buprenorphine 
maintenance therapy 
were excluded from 
the study. 
 
Neonates less than 
28 weeks’ gestation 
were excluded 
(n=2). The ability of 
the placenta to 
metabolize 
methadone or store 
buprenorphine prior 
to the third trimester 
is not yet fully 
understood. 
studies. Significance 
was set at p  .05. 
gestational age infants, and BMT 
showing more neonates with larger for 
gestational age diagnosis.  
 
Length of Stay:  
Maternal methadone dose and 
accompanying use of benzodiazepines 
increased the length of stay by 8.6 days 
while women on MMT who breastfed 
their neonates shortened their infants’ 
length of stay. Infants with prenatal 
exposure to methadone who were 
breastfed were discharged home earlier 
than those infants who were formula-fed.  
 
A positive relationship between maternal 
methadone dose and NAS was displayed 
in this study.  
 
Benzodiazepine use is a predictor variable 
for length of treatment for NAS. Neonates 
exposed to methadone and 
benzodiazepines while in utero, and who 
were born at term had significantly longer 
length of treatment for NAS when 
compared with unexposed neonates or to 
exposed neonates born prematurely. 
  
Associated exposure to SSRIs with MMT 
did not prolong length of stay.  
 
Infant feeding method was negatively 
related to length of stay, suggesting that 
breastfeeding may be protective for 
neonates withdrawing from opioids.  
 
Breastfeeding is associated with a 
decreased rate of infant treatment for 
withdrawal from prenatal methadone or 
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buprenorphine exposure. If the maternal 
urine drug screen is negative for illicit 
substances upon admission, breastfeeding 
should be permitted and encouraged for 
mothers. 
 
Neonates exposed to buprenorphine 
experienced less severe NAS and shorter 
length of stay than those exposed to 
methadone by seven days.  
 
Limitations:  
The study was dependent on the 
availability of medical records and the 
accuracy of documentation of exposure 
history to a number of substances of 
interest.  
 
Maternal drug use was mostly determined 
by self-report, which may be unreliable, 
and should be taken in to consideration.  
There was difficulty finding information 
in the medical record about 
commencement dates regarding opioid 
replacement therapy, SSRIs, or 
benzodiazepines.  
 
Maternal length of time in addiction 
treatment, number of treatment relapses, 
time of initiation of MMT or BMT 
relative to gestational age and duration of 
such therapy, also vary widely, and 
should be taken into consideration.  
 
The study did not examine neonatal drug 
regimen, and it was not controlled across 
all groups.  
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Short et al. 
(2016)  
United States 
of America  
Retrospective 
cohort study 
 
The purpose 
of this 
population-
based study 
was to 
examine the 
association 
between 
breastfeeding 
and length of 
hospital stay 
among 
infants 
diagnosed 
with NAS. 
n=3,725 Breastfeeding at 
discharge was used 
to determine 
breastfeeding status.  
 
Infant and maternal 
characteristics were 
compared by 
breastfeeding status 
and the association 
between 
breastfeeding and 
infant length of 
hospitalization was 
assessed. 
Inclusion: 
Single in-hospital 
births to resident 
mothers in 
Pennsylvania 
between January 1, 
2012 and December 
31, 2014.  
 
A total of 20 
matching iterations 
were performed 
using variables such 
as child date of 
birth, gender, race, 
ethnicity, zip code, 
facility/hospital 
number, gestation, 
and birth weight.  
 
Exclusion:  
Infants born less 
than 34 weeks of 
gestation were 
excluded to control 
for possible 
iatrogenic NAS.  
Infants who were 
breastfed were 
significantly more 
likely to have a 
normal birth weight 
(86.9% versus 81.6%, 
p < 0.0001) and be 
born term (89.6% 
versus 86.2%, p < 
0.002) than infants 
who were not 
breastfed.  
They were also 
significantly more 
likely to have 
mothers who had 
greater than a high 
school education 
(44.9% versus 32.6%, 
p < 0.0001), were 
married (25.2% 
versus 16.9%, p < 
0.0001), and had a 
history of prenatal 
care (98.8% versus 
94.0%, p < 0.0001).  
 
Breastfed infants 
were significantly 
less likely to have 
mothers who smoked 
(70.1% versus 81.0%, 
p < 0.0001) or 
received Medicaid 
(66.6% versus 72.6%, 
p = 0.0001) 
compared to non-
breastfed infants. 
 
NAS infants who are breastfed have 
shown to have a significantly shorter 
length of stay than non-breastfed NAS 
infants, even after controlling for 
differences in maternal and infant 
characteristics.  
 
There is an inverse relationship between 
breastfeeding and length of hospital stay 
and other adverse outcomes among NAS 
infants.  
 
The nearly 10% reduction associated with 
length of stay for infants who were 
breastfed represents as an opportunity for 
significant cost savings.  
 
A shortened length of stay may equate to 
potential savings of more than $3,000 per 
inpatient treatment day.  
 
Lower rates of breastfeeding among NAS 
infants are not unexpected and could be 
due to higher NICU admission rates 
and/or the physical symptoms more 
commonly found in this population, 
which could make breastfeeding difficult.  
 
The act of breastfeeding, rather than the 
actual breast milk itself, is what likely 
impacts NAS infants.  
 
Other nonpharmacological interventions 
both compliment and support the act of 
breastfeeding itself, such as skin to skin 
contact, and kangaroo care. Rooming-in 
and uninterrupted postpartum contact 
between mother and infant has shown to 
positively affect infants affected by NAS.  
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No differences in 
NICU admission or 
maternal age, race, 
ethnicity, or WIC use 
were found. 
 
There was a 
significant inverse 
relationship 
between 
breastfeeding and 
length of stay 
(B = -0.085, p = 
0.008).  
 
 
Limitations:  
The variability in assessment of NAS 
may lead to inaccuracies in the 
classification of NAS.  
 
The lack of information regarding both 
in-utero exposure and postnatal treatment 
for NAS impacts the clinical presentation 
of NAS through: Substance(s), timing, 
and amount of last maternal use. This 
study also did not identify drugs used to 
treat maternal opioid dependence, 
although treatment may influence length 
of stay. 
 
Maternal opioid abuse and the legitimate 
use of an opioid prescription was not 
differentiated in this study.  
 
There was a lack of specific data about 
breastfeeding practices. There was only 
one question used to assess the 
breastfeeding status of the infant at 
discharge and it did not differentiate 
between exclusive breastfeeding, and 
mixed feeding of breast milk and formula.  
White-Traut 
et al. (2002)  
United States 
of America  
Prospective 
design with 
random 
assignment of 
drug-exposed 
and 
nonexposed 
newborns to 
control and 
experimental 
groups.  
 
n=45 total 
drug-
exposed 
newborns 
 
n=21 drug-
exposed 
control 
newborns 
 
n=24 drug-
exposed 
ATVV intervention: 
A 15-minute 
procedure consisting 
of infant-directed 
talk, continuous 
throughout the 
procedure 
(auditory), 10 
minutes of light 
stroking/infant 
massage (tactile), 
eye-to-eye contact 
Inclusion:  
Sample consisted of 
72 nonexposed and 
45 prenatally drug-
exposed 24- to 48-
hour-old neonates 
with a gestational 
age of 35 to 41 
weeks.  
 
Exclusion:  
Both the drug-
exposed newborn 
group, and the 
nonexposed newborn 
group were 
behaviorally similar 
at baseline. 
However, the 
experimental group 
(drug-exposed 
newborns) 
experienced a 
The nonexposed infants who received 
the ATVV intervention had 19% more 
alertness during the intervention period 
than did the nonexposed control infants 
during the same period of observation.  
 
The increased arousal of the drug-
exposed experimental group was 
characterized by 13.66% more alertness 
than the drug-exposed control infants at 
the end of the extended postintervention 
period. 
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The purpose 
of this study 
was to 
compare 
responses of 
drug-exposed 
and 
nonexposed 
newborns to 
auditory, 
tactile, visual, 
and vestibular 
intervention. 
experiment
al 
newborns. 
 
n=72 total 
nonexposed 
newborns  
 
n=29 
nonexposed 
control 
newborns 
 
n=43 
nonexposed 
experiment
al newborns 
during alert periods 
(visual), and vertical 
rocking of the 
swaddled infant for 
5 minutes post 
massage 
(vestibular).  
 
Infant behavioral 
state (quiet sleep, 
active sleep, 
drowsy, quiet alert, 
active alert, crying, 
and indeterminate 
state) were 
documented.  
 
Pulse rate and pulse 
waveform were 
continuously 
recorded with a 
pulse oximeter.  
Infants greater than 
48 hours old, had 
symptoms of active 
withdrawal, were 
likely to be 
discharged before 
completion of the 
second ATVV 
intervention, had 
congenital 
malformations, or 
required 
medications, 
treatments, or 
intensive/intermedia
te care.  
significant decrease 
in quiet sleep 
[F(1,70)=14.83, p=0.
000] and an increase 
in alertness 
[F(1,70)=5.18, p=0.0
26] during the 
intervention. 
 
In the experimental 
group during 
baseline, a trend 
toward an increased 
proportion of time 
spent in alert states 
(p=0.051) was noted. 
 
During the 
administration of the 
ATVV intervention, 
the control group 
experienced more 
quiet sleep 
[F(1,43)=9.04, p=0.0
04] and less 
alertness 
[F(1,43)=6.13, p=0.0
17]. 
 
The increased 
arousal of the drug-
exposed 
experimental group 
persisted throughout 
the immediate post 
[F(1,43)=5.04, p=0.0
30] and extended 
postintervention 
 
The drug-exposed control infants 
displayed more active sleep than the 
nonexposed control infants during the 
time that their experimental counterparts 
received ATVV intervention 
[F(1,49)=9.35, p=0.004]. 
 
When compared at baseline, a trend 
toward greater active sleep (p=0.092) 
was shown for the drug-exposed 
experimental group. 
 
The nonexposed experimental infants 
displayed greater alertness compared to 
the drug-exposed experimental infants 
but did not achieve statistical 
significance in this study. However, it 
supports the previously reported ability 
of the ATVV intervention to enhance 
both autonomic and behavioral function 
in infants.  
 
Drug exposure alone, results in 
alterations in infant behavioral state, and 
suggests that the ATVV intervention 
modified the behavioral responses of 
drug-exposed experimental infants 
similar to what is seen in nonexposed 
experimental infants, which supports the 
findings that the ATVV intervention 
promotes optimal behavior in drug-
exposed infants, and is of significant 
clinical value. 
 
Limitations: 
There was a smaller sample size of 
infants, and the research was conducted 
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[F(1,43)=4.13, p=0.0
49] periods. 
 
The drug-exposed 
control infants had 
more active sleep 
[F(1,49)=7.01, p=0.0
11] and less 
alertness 
[F(1,49)=7.42, p=0.0
09] than the 
nonexposed control 
infants.  
 
A strong, significant 
correlation between 
pulse rate and infant 
behavioral state was 
found for the 
combined group of 
nonexposed infants 
(r=0.840, p=0.001) 
whether they were 
assigned to the 
control 
(r=0.938, p=0.006) 
or experimental 
group 
(r=0.979, p=0.001).  
 
over a 12-hour period during early 
postnatal adjustments.  
 
The group of mothers who participated 
may be different from the mothers who 
refused to participate. 
 
Self-reports are often unreliable, and were 
evident in this study.  
 
Infants were considered “nonexposed” if 
maternal and/or infant urine toxicology 
was negative, and/or if a history of drug 
use during pregnancy was not identified 
through medical record screening.  
 
Various lengths of exposure to a wide 
range of drugs may have contributed to 
affecting behavior.  
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